About US
Contact us
-
2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 3rd station--Guangzhou was successfully concluded2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 3rd station--Guangzhou was successfully concluded 2013 PhexTour （Pharma Excipients Technical Application National Tour2013/7/26
-
J&J getting ugly OTC episode behind itFort Washington plant nearly ready for FDA reinspection; J&J settles shareholder suit tied to its failings Sometime in the future, Johnson & Johnson ($JNJ) expects it will not have to talk ab2013/7/19
-
As bribery probe intensifies, China confines GlaxoSmithKline finance chief to its bordersGlaxoSmithKline's ($GSK) finance chief inChinais stuck. The government won't let him cross the border. In the midst of investigating the company for bribery, officials confined Steve Nechelput to the2013/7/19
-
Novartis raises guidance thanks to no-show Diovan genericWhy exactly a generic version of Novartis' blood-pressure drugDiovanhas yet to hit the market is a bit of a mystery, but one thing is clear: The company is benefiting from the delay. Novartis ($NVS),2013/7/18
-
Lilly freezes salaries ahead of patent loss for CymbaltaEli Lilly's ($LLY) CEOJohn Lechleiterwas out for a couple of months as he dealt with some heart issues. He recently returned, and guess what he brought with him? More bad news for employees. The Indi2013/7/18
-
CFDA releases the first issue of 2013 National Medical Device Quality AnnouncementChina Food and Drug Administration (CFDA) recently released the first issue of 2013 National Medical Device Quality Announcement and publicized the quality sampling and testing results of balloon dila2013/7/16
-
China calls GSK 'godfather' in alleged bribery schemeProbe turns up information other drugmakers doing the same Western drugmakers holding their breath, worried that they may be the next target for bribery inChina, can't yet come up for air. Chinese la2013/7/16
-
Roche may want Alexion, but is the price right?Roche may have the wherewithal to bid for Alexion and an appetite for the company's rare-disease drugs. But it might not have the stomach for the price. Roche ($RHHBY) is reportedly scouting for fina2013/7/16
-
Novartis CEO Jimenez says China is a difficult market, but worth itChinais a huge market and offers huge potential for pharma. But it is an increasingly challenging place to do business for Western drugmakers, as GlaxoSmithKline's ($GSK) run-in with authorities over2013/7/15
-
Telegraph: Sources say 30 GSK employees under house arrestChina-watchers think probes part of effort to divert attention away from domestic shortcomings Reports are starting to put a few details around what is going on with more than two dozen GlaxoSmithKli2013/7/15